Lerociclib/Fulvestrant Improves PFS, Tolerability in HR+/HER– Breast Cancer
Selective oral CDK4/6 inhibitor lerociclib (GB491) plus fulvestrant (Faslodex) elicited a greater progression-free survival (PFS) benefit and tolerability compared with placebo plus fulvestrant in patients with hormone receptor (HR)–positive/HER2– …